Trials / Completed
CompletedNCT03187912
Accelerated Corneal Cross-linking With Different Riboflavin Solutions
Effect-evaluation of an Accelerated Corneal Cross-linking Protocol With Different Riboflavin Solutions
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Following the Bunsen-Roscoe law, accelerated cross-linking protocols with higher irradiation intensities and shorter irradiation times have been introduced. In addition, new riboflavin solutions with HPMC (hydroxylpropyl methylcellulose) instead of dextran found its way into CXL-treatment. The aim of this trial is to evaluate clinical outcomes in an accelerated corneal collagen cross-linking protocol with different riboflavin solutions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Riboflavin | Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively |
Timeline
- Start date
- 2016-09-19
- Primary completion
- 2020-03-30
- Completion
- 2020-03-30
- First posted
- 2017-06-15
- Last updated
- 2021-03-03
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT03187912. Inclusion in this directory is not an endorsement.